We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+41.99%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$7.04B
AUM Growth
+$1.98B
Cap. Flow
-$1.2B
Cap. Flow %
-17.09%
Top 10 Hldgs %
79.89%
Holding
87
New
12
Increased
14
Reduced
15
Closed
5

Top Buys

Rank Stock Value
1
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$51.7M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$19.5M
3
DSCI
Derma Sciences, Inc. Common Stock (DE)
DSCI
+$16.6M
4
QCOR
QUESTCOR PHARMA INC
QCOR
+$13.7M
5
XOMA
Xoma
XOMA
+$12.5M

Top Sells

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$195M
2
VPHM
VIROPHARMA INC
VPHM
+$96M
3
CLVS
Clovis Oncology, Inc.
CLVS
+$15.8M
4
AEGR
Aegerion Pharmaceuticals
AEGR
+$8.82M
5
INFI
Infinity Pharmaceuticals, Inc.
INFI
+$8.22M

Sector Composition

Rank Sector Weight
1 Healthcare 42.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLVS
26
DELISTED
Clovis Oncology, Inc.
CLVS
$18.3M 0.26%
301,744
-223,369
-43% -$15.8M
ARWR icon
27
Arrowhead Research
ARWR
$11.9B
$17.9M 0.25%
+3,140,000
New +$12.1M
CHTP
28
DELISTED
CHELSEA THERAPEUTICS INT'L LTD
CHTP
$17.3M 0.25%
5,794,753
+1,018,966
+21% +$2.93M
INSM icon
29
Insmed
INSM
$22.6B
$14.8M 0.21%
945,803
+150,000
+19% +$1.91M
KYTH
30
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$12.1M 0.17%
265,000
+100,000
+61% +$2.99M
SGYP
31
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$11.9M 0.17%
2,644,787
– –
AMBI
32
DELISTED
Ambit Biosciences Corp
AMBI
$11.6M 0.16%
747,962
– –
GYRE icon
33
Gyre Therapeutics
GYRE
$630M
$11M 0.16%
+2,626
New +$10.6M
INFI
34
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$10.2M 0.15%
586,936
-429,497
-42% -$8.22M
ACGN
35
DELISTED
Aceragen Inc
ACGN
$10.2M 0.15%
43,168
+10,047
+30% +$2.01M
ARRY
36
DELISTED
Array Biopharma Inc
ARRY
$9.33M 0.13%
1,500,000
– –
ANAC
37
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$9.31M 0.13%
876,463
– –
IONS icon
38
Ionis Pharmaceuticals
IONS
$9.03B
$9.27M 0.13%
247,036
– –
MTEM
39
DELISTED
Molecular Templates, Inc.
MTEM
$8.61M 0.12%
11,227
+1,560
+16% +$1.28M
PTLA
40
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$8.02M 0.11%
299,911
-100,003
-25% -$2.38M
PRTA icon
41
Prothena Corp
PRTA
$441M
$7.48M 0.11%
369,650
– –
QLTI
42
DELISTED
QLT Inc
QLTI
$7.11M 0.1%
1,535,863
– –
OSIR
43
DELISTED
Osiris Therapeutics, Inc. Common Stock
OSIR
$6.25M 0.09%
+375,282
New +$5.55M
OMER icon
44
Omeros
OMER
$826M
$5.93M 0.08%
+608,404
New +$3.63M
XNPT
45
DELISTED
XENOPORT, INC.
XNPT
$5.87M 0.08%
1,034,112
– –
AGIO icon
46
Agios Pharmaceuticals
AGIO
$2.08B
$5.59M 0.08%
+200,000
New +$5.52M
IRWD icon
47
Ironwood Pharmaceuticals
IRWD
$593M
$5.46M 0.08%
550,625
-550,434
-50% -$5.4M
NVAX icon
48
Novavax
NVAX
$1.21B
$5.41M 0.08%
+85,846
New +$4.83M
PBYI icon
49
Puma Biotechnology
PBYI
$397M
$5.37M 0.08%
100,000
+16,667
+20% +$898K
BDSI
50
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$4.59M 0.07%
846,005
-54,500
-6% -$262K
1
2
3 4

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2013 Portfolio in Review

As of Q3 2013, Baker Bros. Advisors held 87 positions worth $7.04B, up 39% from $5.06B the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Baker Bros. Advisors withdrew a net $1.2B in Q3 2013, closing 5 positions and reducing 15 holdings. Its most notable exit was Arqule Inc, an estimated $2.04M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 42% of assets, up from 39% a quarter earlier.

Against the trend, Baker Bros. Advisors opened a new position in Mirati Therapeutics, Inc. Common Stock worth $30M.

  • Baker Bros. Advisors's largest Q3 2013 buy was Mirati Therapeutics, Inc. Common Stock: 1,980,074 shares worth $30M.
  • Baker Bros. Advisors added most to SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q3 2013, an estimated $51.7M increase.
  • Baker Bros. Advisors's biggest Q3 2013 reduction was PHARMACYCLICS INC, cutting an estimated $195M.
  • Baker Bros. Advisors fully exited Arqule Inc in Q3 2013, selling an estimated $2.04M.
  • Baker Bros. Advisors's ten largest holdings make up 80% of its $7.04B portfolio in Q3 2013.
  • Baker Bros. Advisors opened 12 new positions and closed 5 in Q3 2013.
  • Baker Bros. Advisors's portfolio value rose 39% quarter-over-quarter to $7.04B.

Based on Baker Bros. Advisors's 13F filing for Q3 2013, filed 14 Nov 2013.